Last reviewed · How we verify
TDM-180935 topical ointment 1.0%
At a glance
| Generic name | TDM-180935 topical ointment 1.0% |
|---|---|
| Sponsor | Technoderma Medicines Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of TDM-180935 in Atopic Dermatitis Patients (PHASE2)
- A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDM-180935 topical ointment 1.0% CI brief — competitive landscape report
- TDM-180935 topical ointment 1.0% updates RSS · CI watch RSS
- Technoderma Medicines Inc. portfolio CI